Analysis of the prophylactic effect of thymosin drugs on COVID-19 for 435 medical staff: A hospital-based retrospective study.

Liu, Xiulan; Liu, Yi; Wang, Liuming; Hu, Luhong; Liu, Dong; Li, Juan

BACKGROUND To explore the role of thymosin drugs in the prevention of a novel coronavirus disease (COVID-19), we analyzed the preventive effects of different medication timings on health medical staff, and then provided recommendations for pharmaceutical monitoring of the thymus drugs. METHODS We conducted a hospital-based retrospective study on 435 medical staff who might use or not to use thymosin drugs for preventive medicines in our hospital. For the prophylactics, medical staff was prevented from pre-exposure prophylaxis (risk prevention of exposure to COVID-19 patients before using thymosin drugs) and post-exposure prophylaxis (risk prevention of exposure to COVID-19 patients with after using thymosin drugs). Effectiveness and safety of thymosin drugs in the prevention and control of COVID-19 application, in real world data research for the application of the drug in COVID- 19. RESULTS In the similar exposure environment, compared to medical staff who did not take preventive medicine, the use of thymosin drugs, before exposure and after exposure had an insignificant effect, and the adverse drug reaction (ADR) was increased, especially when thymosin drugs used together with α-interferon. CONCLUSIONS Thymosin drugs had no significant effect on the prevention of COVID-19 before and after exposure for medical staff, along with certain ADRs, so preventive medication of thymosin drugs was not recommended. This article is protected by copyright. All rights reserved.